Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure

Inclusion Criteria: * Age more than 18 years old, no gender limit. * According to the Diagnosis and Treatment of Primary Lung Cancer (2018 edition), non-small cell lung cancer (NSCLC) was diagnosed by histopathology. * Tumor Node Metastasis (TNM) staging is II-III. * According to the National Comprehensive Cancer Network (NCCN) guidelines, patients who had failed, refused, or were not suitable for standard treatment (surgery, chemoradiotherapy, targeted) after consultation. * Eastern Cooperative Oncology Group (ECOG), Performance Status (PS) Score ≤ 2. * Estimated survival time is more than 3 months. * The patient has signed informed consent. Exclusion Criteria: * The patient has previously received interventional therapy \[iodine seed implantation, ablation, bronchial arterial chemoembolization (BACE) therapy\], or received immunotherapy during the first-line standard treatment. * The patient is accompanied by other malignant tumors and had not been cured. * White blood cell \< 3×10\*9/L, absolute value of neutrophils \< 1.5×10\*9/L, neutrophil/lymphocyte ratio ≥ 3, platelet count \< 50×10\*9/L, hemoglobin concentration \< 90 g/L. * Liver and kidney dysfunction (creatinine \> 176.8 μmol/L; aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \> 2 times the upper limit of normal). * Uncorrectable coagulopathy or active hemoptysis. * Patient with active infections requires antibiotic treatment. * Patient has uncontrollable hypertension, diabetes, and cardiovascular disease with obvious symptoms. * Allergy to contrast agents. * Women with pregnancy or lactation.